Cyclosporine withdrawal in stable renal transplant recipients [2]

Transplantation

Volumn 76, Issue 8, 2003, Pages 1240-1241

  Kumar Mahawar, Kamal ^a  

^a Caithness General Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN;

DRUG WITHDRAWAL; GRAFT FAILURE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; LETTER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION;

EID: 0242363642     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000084821.39482.93     Document Type: Letter

References (4)

1. Pascual M, Curtis J, Delmonico FL, et al. A prospective randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation. Transplantation 2003; 75: 1501.
2. Abramowicz D, Manas D, Lao M, et al. Cyclosporine withdrawal from a mycophenolate mofetil containing immunosuppressive regimen in stable kidney transplant recipients: a randomized controlled study. Transplantation 2002; 74: 1725.
3. Gregoor PJS, Van Gelder T, Van Besouw NM, et al. Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction. Transplantation 2000; 70: 143.
4. Johnson RW, Kreis H, Oberbauer R, et al. The Sirolimus Tricontinental Renal Transplant Study Group. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777.